Intravenous Minocycline: A Review in Acinetobacter Infections.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

24 citing papers in PubMed, 39 citations in OpenAlex.

1. "Antimicrobial susceptibility of carbapenem-resistant Acinetobacter baumannii against tetracycline, doxycycline, tigecycline, minocycline and colistin: experience from a tertiary care hospital in Karachi".BMC microbiology · 2026
   Article
2. Phage Therapy forAntibiotics (Basel, Switzerland) · 2025
   Review
3. Turning the Tide Against Carbapenem-resistantOpen forum infectious diseases · 2025
   Article
4. Antimicrobial agents and chemotherapy · 2025
   Review
5. Carbapenem Resistance inMicroorganisms · 2025
   Review
6. Treatment Approaches for Carbapenem-Resistant Acinetobacter baumannii Infections.Drugs · 2025
   Review
7. The intricacies ofFrontiers in microbiology · 2025
   Review
8. An Ancient Drug for a Modern Era: Minocycline for the Treatment of Multi-Drug-Resistant Acinetobacter baumannii.Cureus · 2024
   Article
9. Treatment of infections caused by carbapenem-resistantFrontiers in cellular and infection microbiology · 2024
   Review
10. Minocycline and the SPR741 Adjuvant Are an Efficacious Antibacterial Combination forAntibiotics (Basel, Switzerland) · 2022
    Article
11. Carbapenem-resistant Acinetobacter baumannii: Colonization, Infection and Current Treatment Options.Infectious diseases and therapy · 2022
    Review
12. Polymyxin B Combined with Minocycline: A Potentially Effective Combination against blaMolecules (Basel, Switzerland) · 2022
    Article
13. Emerging Treatment Options for Multi-Drug-Resistant Bacterial Infections.Life (Basel, Switzerland) · 2021
    Review
14. Antimicrobial Effects of Minocycline, Tigecycline, Ciprofloxacin, and Levofloxacin againstAntibiotics (Basel, Switzerland) · 2021
    Article
15. Pulmonary Embolism and Splenic Infarction after Minocycline Infusion in a Patient with Polycythemia Vera.Internal medicine (Tokyo, Japan) · 2021
    Article
16. Drugs for Gram-Negative Bugs From 2010-2019: A Decade in Review.Open forum infectious diseases · 2020
    Review
17. The Role of Minocycline in the Treatment of Nosocomial Infections Caused by Multidrug, Extensively Drug and Pandrug ResistantMicroorganisms · 2019
    Review
18. In vitro activity of minocycline combined with aminoglycosides against Klebsiella pneumoniae carbapenemase-producing K. pneumoniae.The Journal of antibiotics · 2018
    Article
19. A Retrospective Cohort Analysis Shows that Coadministration of Minocycline with Colistin in Critically Ill Patients Is Associated with Reduced Frequency of Acute Renal Failure.Antimicrobial agents and chemotherapy · 2018
    Article
20. Similarities and differences between doxycycline and minocycline: clinical and antimicrobial stewardship considerations.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2018
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors at 2 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as